Studies have shown that HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) can inhibit the production of HIF-1α protein and target genes in multiple myeloma under hypoxia, indicating that it may serve as an HIF-1α inhibitor against cancers. This evidence concerns the gene HIF1A and AL amyloidosis.